NPO Petrovax Pharm will increase the manufacture of active pharmaceutical ingredients (APIs) and finished dosage forms (tablets and suppositories) of original local pharmaceuticals. It is planned to invest 907 m RUB into a production capacity upgrade project at the company’s basic manufacturing site in Podolsk district of Moscow region; 300 m RUB of the above sum will be provided by the Industry Development Fund (IDF) as a low-interest loan. The IDF Expert Council made a relevant decision this week.
The project partner will be Lab & Pharma, spol. s r.o.; Petrovax Pharm maintains cooperation with this company for many years. The construction of the new production line is to be completed through the end of 2017 or in the 1st quarter of 2018. The project implementation will make it possible for Petrovax Pharm to increase the output of APIs 2.5-fold, tablets — 7-fold, and suppositories — 4-fold by 2019. For Russia’s healthcare practice, this means guaranteed supplies of up-to-date efficacious pharmaceutical products used in the relevant areas of medicine such as immunology, gynecology, urology, surgery, and pediatrics.
The new manufacturing facilities will fully comply with the Russian and European GMP standards, which will provide for expanding partner projects on manufacture localization and exports.
NPO Petrovax Pharm LLC is a Russian developer and manufacturer of innovative pharmaceuticals and vaccines. The company’s key focus areas are manufacturing of influenza and pneumococcal vaccines for the National Immunization Schedule as well as the development and production of immunobiological products.
NPO Petrovax Pharm’s production and warehousing complex located in Podolsk district of Moscow region was launched into operation in 2008. Presently, it is one of the most advanced and hi-tech full-cycle biopharmaceutical facilities in Russia. It has GMP EU and ISO:9001 certificates of conformity.
The production areas provide for manufacturing APIs and finished pharmaceuticals filled into disposable syringes, ampoules, vials, and polymer containers in liquid, soft, and solid dosage forms. The production facilities provide for manufacturing more than 160 m doses of immunobiological products per annum.
NPO Petrovax Pharm has more than 600 employees. This is an Interros Group company.